Gerard Porter

Biographic Data

ID6408012
NAMEGerard Porter
GIVEN NAMESGerard
FAMILY NAMEPorter
SIGNATUREPORTER G
AFFILIATIONSSchool of Law, University of Edinburgh, Edinburgh, UK
ORCID0000-0002-1566-039X
VERIFIEDYes
TOTAL WORKS6
TOTAL CITATIONS2
WORKS AS AUTHOR6
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2013
LATEST PUBLICATION YEAR2020
H-INDEX1

  • Using ‘smart regulation’ to tackle antimicrobial resistance in low-income and middle-income countries

    Open AccessGerard Porter, Jyoti Joshi et al.ARTICLEBMJ Global Health2020

    Low-income and middle-income countries are aligning their National Action Plans on antimicrobial resistance with WHO's 2015 Global Action Plan. Regulation is a key tool for operationalising national standards aimed at optimising the use of antimicrobial medicines. On its own, the traditional command-and-control approach to regulation is poorly suited to this challenge. 'Smart regulation' can be used to supplement, finetune and improve on more tra…

  • Regulating clinical trials in India

    Open AccessGerard PorterARTICLEDeveloping World Bioethics2018

    The relationship between the ethical standards for the governance of clinical trials and market forces can be complex and problematic. This article uses India as a case study to explore this nexus. From the mid‐2000s, India became a popular destination for foreign‐sponsored clinical trials. The Indian government had sought to both attract clinical trials and ensure these would be run in line with internationally accepted ethical norms. Reports of…

  • How Civil Society Organisations Changed the Regulation of Clinical Trials in India

    Open AccessSakari Sariola, Roger Jeffery et al.ARTICLEScience as Culture2018Cited by: 2References: 10

    In 2005 India changed its pharmaceutical and innovation policy that facilitated a dramatic increase in international clinical trials involving study sites in India. This policy shift was surrounded by controversies; civil society organisations (CSOs) criticised the Indian government for promoting the commercialisation of pharmaceutical research and development. Health social movements in India fought for social justice through collective action, …

  • Scotland the Brand – Marketing the Myth

    Open AccessGillian Black, Rachael Craufurd Smith et al.ARTICLEScottish Affairs2015References: 3

    The paper considers the role of Scottish culture and history, real or imagined, in the commercialisation of iconic Scottish creations such as tartan and Scotch whisky. It notes that many of the forms of legal protection available to the producers of such products were developed to encourage individual innovation, not designed to address communal interests in the preservation of national or group identities and heritage. This may be one reason why…

  • Preventing the selection of “deaf embryos” under the Human Fertilisation and Embryology Act 2008

    Open AccessGerard Porter, Malcolm K SmithARTICLENew Genetics and Society2013

    Section 14(4) of the Human Fertilisation and Embryology Act 2008 imposes – within the general licensing conditions listed in the Human Fertilisation and Embryology Act 1990 – a prohibition to prevent the selection and implantation of embryos for the purpose of creating a child who will be born with a “serious disability.” This article offers a perspective that demonstrates the problematic nature of the consultation, review, and legislative reform…

  • Human rights and ethical considerations for a tobacco-free generation

    Open AccessYvette van der Eijk, Gerard PorterARTICLETobacco Control2013

    In recent years, a new tobacco 'endgame' has been proposed: the denial of tobacco sale to any citizen born after a certain year, thus creating new tobacco-free generations. The proposal would not directly affect current smokers, but would impose a restriction on potential future generations of smokers. This paper examines some key legal and ethical issues raised by this proposal, critically assessing how an obligation to protect human rights migh…